Comparative study of effects and tolerability of Solifenacin and Oxybutynin on the urinary symptoms of multiple sclerosis patients.

comparative study of effects and tolerability of solifenacin and oxybutynin on the urinary symptoms of multiple sclerosis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190217042727N1

Enrollment

Registered

2019-04-15

Start date

2019-06-10

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group:the first intervention group will receive 5 mg of solifenacin(producted by Abidi pharmaceutical company)per day for 2 months. Intervention 2: Intervention group: In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study will include people with multiple sclerosis who complain from urinary symptoms such as frequency,urgency and voiding dysfunction and their informed consent will be obtained.

Exclusion criteria

Exclusion criteria: patients who suffer from other diseases such as kidney diseases that can cause urinary symptoms. patients with contraindications to use anticholinergic drugs such as glaucoma , BPH and pregnant women. patients who have taken other drugs to control urinary symptoms

Design outcomes

Primary

Measure	Time frame
Severity of urinary symptoms. Timepoint: At the end of eighth week. Method of measurement: questioning patients and visual observation(Visual Analogue Scale).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Esmaeili

Kermanshah University of Medical Sciences

narges.esmaeili.dr.92@gmail.com+98 83 3427 4618

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026